- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech High Growth Potential Companies
Swiss Pharmaceuticals & Biotech High Growth Potential Companies
Results
13
Companies with a Future performance score of at least 3, ordered by Future performance score.
13 companies
Newron Pharmaceuticals
Market Cap: CHF 314.2m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 15.74
7D
3.1%
1Y
124.9%
Kuros Biosciences
Market Cap: CHF 1.1b
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 27.24
7D
-0.2%
1Y
11.9%
Cosmo Pharmaceuticals
Market Cap: CHF 1.1b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 66.10
7D
0.6%
1Y
5.9%
Sandoz Group
Market Cap: CHF 23.2b
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
SDZ
CHF 53.90
7D
-2.4%
1Y
35.2%
SKAN Group
Market Cap: CHF 1.1b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 47.50
7D
-3.7%
1Y
-35.1%
Galderma Group
Market Cap: CHF 35.0b
Operates as a dermatology company worldwide.
GALD
CHF 147.50
7D
-3.6%
1Y
71.6%
Lonza Group
Market Cap: CHF 37.2b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 529.60
7D
-4.5%
1Y
2.4%
PolyPeptide Group
Market Cap: CHF 763.8m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 23.15
7D
-2.7%
1Y
-14.3%
Tecan Group
Market Cap: CHF 1.7b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 133.40
7D
-4.4%
1Y
-36.5%
Bachem Holding
Market Cap: CHF 3.7b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 48.72
7D
-6.1%
1Y
-28.1%
Roche Holding
Market Cap: CHF 265.7b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 310.20
7D
6.8%
1Y
24.5%
Molecular Partners
Market Cap: CHF 127.3m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.41
7D
-3.8%
1Y
-29.1%
Siegfried Holding
Market Cap: CHF 3.0b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 69.00
7D
-9.7%
1Y
-37.3%